FDA Approves Dexcom G4 Platinum Continuous Glucose Monitoring System with Share

January 26, 2015

Dexcom announced today that it has received U.S. Food and Drug Administration (FDA) approval for its Dexcom G4^® PLATINUM Continuous Glucose Monitoring System with Share. The Dexcom Share receiver uses a secure wireless connection via Bluetooth Low Energy (BLE) between a patient's receiver and an app on the patient's smartphone to transmit glucose information to apps on the mobile devices of up to five designated recipients, or "followers," without the need for a dedicated docking cradle. These followers can remotely monitor a patient's glucose information and receive alert notifications from almost anywhere, initially via their Apple^® iPhone^® or iPod^® touch and in the future on Android devices, giving them peace of mind and reassurance when they are apart. The "Share" and "Follower" apps will be available on the Apple App Store at no charge.

"The Dexcom Share receiver represents a significant step forward for our company and our mobile strategy, but more importantly, it will provide a huge improvement for people managing their diabetes and for those parents and caregivers who help them each and every day," said Kevin Sayer, President and Chief Executive Officer of Dexcom. "The FDA understands the importance of this type of innovation and the need to regulate it appropriately, and we could not be more pleased with the speed at which they reviewed and approved this important innovation."

About Dexcom G4 Platinum with Share:

The Share receiver is anticipated to ship to new patients in early March 2015.
All patients who purchased a Share cradle will receive a free upgrade to the Share receiver.
All purchasers of a G4 Platinum receiver from January 1, 2015, until the Share receiver is shipped, will receive a free upgrade to the Share receiver.
There will be a low cost cash upgrade to the Share receiver for those patients who are still under warranty with their existing receiver.
The Share receiver will be compatible with future generation Dexcom sensor systems.

About the De Novo Classification Process:

The FDA reviewed the mobile app software used with the Dexcom Share receiver (both the "Share" app on the patient's phone and the "Follow" app on the caregiver's phone) through its de novo classification process, a regulatory pathway for low- to moderate-risk medical devices that are novel and not substantially equivalent to any legally marketed device. The FDA has specifically classified the apps which communicate with the Share receiver as a secondary display device and has noted that similar devices which provide only secondary display for passive monitoring, but which do not replace the primary real-time display device, will be subject to the same classification, subject to compliance with certain special controls established by the Agency with respect to this secondary display. This means that devices which comply with appropriate FDA regulations, including the special controls, will not be required to submit a premarket notification to the FDA before marketing a secondary display device for continuous glucose monitoring. The Share receiver was still evaluated as a Class III medical device.